Post-Traumatic Stress Disorders Clinical Trial
Official title:
Efficacy of an SSRI in Acute Stress Disorder and PTSD
The purpose of this study is to examine the short-term consequences of trauma and to
determine the effectiveness of the drug sertraline in preventing and treating post-traumatic
stress disorder (PTSD) and acute stress disorder (ASD) symptoms.
ASD and PTSD are common consequences of exposure to traumatic events. Despite growing
evidence of neurobiological dysfunction in ASD and PTSD, the origin of these disorders is
still unknown. This study will attempt to identify psychophysiological markers of ASD and
find an effective treatment for its symptoms.
Victims of serious motor vehicle collisions will be evaluated with clinical assessments and
standardized questionnaires within 2 weeks after the accident. Symptoms of exaggerated
startle, emotional reactivity to trauma-related and trauma-unrelated cues, and cerebellum
functioning will be evaluated. Participants will be randomized to receive either sertraline
or placebo (an inactive sugar pill) for 8 weeks. Psychometric testing and psychological
evaluations will be conducted 4, 10, and 14 weeks after the accident and after a 2-week
taper of the study medication.
Acute stress disorder (ASD) and posttraumatic stress disorder (PTSD) are common consequences
of exposure to traumatic events. Despite growing evidence of neurobiological dysfunction in
ASD and PTSD, the pathogenesis of these disorders is still unknown. Drs. Osuch and Ursano
(Uniformed Services University of the Health Sciences) have received support to conduct a
14-week study that will investigate the efficacy of the serotonergic medication sertraline
(Zoloft) in the treatment and prevention of posttraumatic psychiatric sequelae in ASD
victims. The present project is an amendment to Drs. Osuch and Ursano's study. It will
attempt to identify early psychological and neurobiological abnormalities in ASD. More
specifically, the present project will examine to what extent sensitization and conditioning
processes, as well as emotional dysregulation, contribute to ASD. We also propose to
investigate the potential association between cerebellum dysfunction and peritraumatic
dissociations. To accomplish this goal, a series of three experiments will be implemented to
investigate: 1) the symptom of exaggerated startle; 2) emotional reactivity to
trauma-related and trauma-unrelated cues; and 3) cerebellum functioning using eyeblink
conditioning. This study will inform on the short-term consequences of trauma, will help
identify potential psychophysiological markers of ASD that emerge following trauma, and will
examine the effects of an SSRI on preventing trauma-related neurobiological deficits.
We specifically propose to:
1. Characterize psychophysiological responses in ASD victims shortly after trauma;
2. Assess the effect of sertraline treatment on these psychophysiological responses.
To accomplish aim 1, non-treated ASD victims will be compared to two control groups, a
non-ASD trauma group and a non-trauma healthy group. The two control groups will be used to
disentangle the effect of trauma from the effect of acute stress disorder. To accomplish aim
2, the ASD sertraline group will be compared to the ASD placebo group following treatment.
Forty victims of serious motor vehicle collision (MVC) with ASD will be recruited from a
community hospital emergency room and evaluated with clinical assessments, and standardized
questionnaires within 2 weeks after the MVC. The subjects will then be randomized to either
sertraline or placebo for 8 weeks duration. Psychometric testing and psychological
evaluations will be conducted at 4, 10 weeks post-MVC, and after a 2-week taper of the
medication and 2 more weeks (14 weeks post-MVC).
We hypothesize that ASD patients will show:
An enhancement or sensitization of baseline startle;
An increase in autonomic arousal and in startle amplitude to trauma-related cues;
A delayed eyeblink conditioning;
Normalization of these deficits after sertraline treatment.
This preliminary study is expected to lay the groundwork for a larger study of the early
impact of traumatic events on psychophysiological and psychological processes. In the
long-term, we expect to 1) better characterize the onset of symptoms and their evolution
over time following trauma, 2) identify psychophysiological markers for PTSD, 3) identify
ASD victims at-risk for PTSD, and 4) improve our ability to prevent the development of
chronic psychopathology following trauma.
;
Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04032301 -
Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
|
Phase 1 | |
Withdrawn |
NCT00641173 -
Early Intervention for Post Traumatic Stress Disorder (PTSD)
|
N/A | |
Completed |
NCT00564317 -
KIDNET vs Meditation/Relaxation - a Dissemination Randomized Controlled Trial for the Treatment of Traumatized Children After War in Sri Lanka
|
Phase 3 | |
Recruiting |
NCT02512445 -
Trauma Informed Guilt Reduction Therapy
|
N/A | |
Completed |
NCT00100490 -
Immune and Endocrine Function in Post-Traumatic Stress Disorder
|
N/A | |
Terminated |
NCT03605342 -
Optimal Treatment of Veterans With PTSD and Comorbid OUD
|
Phase 2 | |
Terminated |
NCT02824445 -
To Evaluate the Efficacy of EEG-guided Magnetic Resonant Therapy in War Veterans With Posttraumatic Stress Disorder
|
N/A | |
Recruiting |
NCT03152175 -
Posttraumatic Stress Disorders in Police, Correctional Service Officers, and 911 Operators
|
Phase 2 | |
Completed |
NCT02080351 -
A Simple Cognitive Task to Reduce the Build-Up of Flashbacks After a Road Traffic Accident
|
N/A | |
Completed |
NCT00974402 -
Psychotherapy Treatment of Deployment-Related PTSD in Primary Care Settings
|
N/A | |
Recruiting |
NCT00134446 -
Transcranial Magnetic Stimulation for Post-Traumatic Stress Disorder
|
Phase 4 | |
Not yet recruiting |
NCT02384369 -
Trial of Oral SNC-102 in Subjects With Combat-Related Posttraumatic Stress Disorder
|
Phase 2 | |
Completed |
NCT00120250 -
Eszopiclone for Sleep Disturbance and Nightmares in Post-Traumatic Stress Disorder
|
Phase 4 | |
Completed |
NCT00039715 -
Effects of Hydrocortisone in Patients With Post-Traumatic Stress Disorder
|
N/A | |
Recruiting |
NCT04368689 -
The Feasibility and Examination of the Effects of Floatation-based REST on a Community Sample With PTSD
|
N/A | |
Completed |
NCT01060553 -
Pilot of Acupuncture to Improve Quality of Life in Veterans With TBI and PTSD
|
N/A | |
Completed |
NCT00227357 -
The CORE Buprenorphine Project - An HIV Primary Care Program Demonstration
|
N/A | |
Completed |
NCT02927288 -
Identifying Biomarkers That Distinguish PTSD and mTBI Using Advanced Magnetic Resonance Spectroscopy
|
N/A | |
Completed |
NCT01278316 -
Rural Veterans With Post-traumatic Stress Disorder (PTSD) And Comorbid Mild Traumatic Brain Injury (TBI): A Feasibility Study
|
N/A | |
Completed |
NCT00778960 -
Mechanistic Pathways of Mindfulness Meditation in Post-traumatic Stress Disorder.
|
N/A |